Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
FDA Seeks Quality Information;Legislative Filings to Overturn Preemption Decisions;Supreme Court Prepares To Hear Wyeth v. Levine;Generic Drug Company Runs Afoul of FDA;Approvable,Not Approvable System Being Replaced;New Guidance on Advisory Committees;GMPs No Longer Required for Phase I Biologics;Security to Be Improved at Advisory Committee Meetings;FDA Recommends Genetic Test Before Drug Use;Stronger Warning for TNF-Alpha Blockers;Changes Coming in Post-Approval Review No More “Throw the Drug over the Wall” and Wait;More Labeling Revisions for Tysabri,Epo;Information on Expensive Drugs Being Withheld;Patients Given Right to Be Told About Clinical Trials;Countries to Collaborate on Drug Facility Inspections;California Tries to Halt DTC Genetic Test Sales;PhRMA Revises Marketing Recommendations;Transplant Tourism Decried;Stanford Restricts Use of Drug Company Money for Medical Education;Labeling for Hormone Replacement Therapy Found Adequate